Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy

Open Access
Publisher Website
Google Scholar
Abstract
We developed human mesenchymal stem cell (MSC) lines that could differentiate into various tissue cells including bone, neural cells, bone marrow (BM) stromal cells supporting the growth of hematopoietic stem cell (HSC), and so‐called ‘tumor stromal cells’ mixing with tumor cells. We investigated the applicability of MSC as therapeutic cell transplanting reagents (cytoreagents). Telomerized human BM derived stromal cells exhibited a prolonged lifespan and supported the growth of hematopoietic clonogenic cells. The gene transfer of Indian hedgehog (Ihh) remarkably enhanced the HSC expansion supported by the human BM stromal cells. Gene‐modified MSC are useful as therapeutic tools for brain tissue damage (e.g. brain infarction) and malignant brain neoplasms. MSC transplantation protected the brain tissue from acute ischemic damage in the midcerebral artery occlusion (MCAO) animal model. Brain‐derived neurotrophic factor (BDNF)‐gene transduction further enhanced the protective efficacy against the ischemic damage. MSC possessed excellent migratory ability and exerted inhibitory effects on the proliferation of glioma cells. Gene‐modification of MSC with therapeutic cytokines clearly augmented the antitumor effect and prolonged the survival of tumor‐bearing animals. Gene therapy employing MSC as a tissue‐protecting and targeting cytoreagent would be a promising approach. (Cancer Sci 2005; 96: 149–156)